Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
KYMR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$19.45 - $53.27
Previous CloseN/A
Volume48.51K
Average Volume (3M)591.73K
Market Cap
$3.14B
Enterprise Value$2.93B
Total Cash (Recent Filing)$665.45M
Total Debt (Recent Filing)$85.71M
Price to Earnings (P/E)―
Beta2.53
Next Earnings
Oct 30, 2025EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding71,497,600
10 Day Avg. Volume596,591
30 Day Avg. Volume591,729
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue65.56
Enterprise Value/Gross Profit68.76
Enterprise Value/Ebitda-10.58
Forecast
1Y Price Target
$61.47Price Target Upside45.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageKymera Therapeutics remains significantly ahead of competitor STAT6 programs and owns full rights to the asset, strengthening its competitive position.
Partnership OpportunitiesKymera's ability to deliver highly specific differentiated degraders provides opportunities for non-dilutive capital in the form of partnerships with companies like Sanofi and Gilead.
Pipeline SuccessKymera is the first to reach the milestone with a STAT6 degrader, leading the race in targeting the Th2 inflammatory pathway.
Bears Say
Clinical Efficacy ConcernsThe robust Th2 biomarker suppression in BroADen may not necessarily translate into clinically meaningful EASI 75 and pruritus NRS improvements on Day 28.
Investor ConfusionThe rationale for the second dose in the Ph 1b is driving some investor confusion.
Stock VolatilityThe addition of a second dose in the Phase 1b study drove early weakness in shares, though it's unclear if the second dose is higher or lower.
Kymera Therapeutics News
KYMR FAQ
What was Kymera Therapeutics’s price range in the past 12 months?
Kymera Therapeutics lowest stock price was $19.45 and its highest was $53.27 in the past 12 months.
What is Kymera Therapeutics’s market cap?
Kymera Therapeutics’s market cap is $3.14B.
When is Kymera Therapeutics’s upcoming earnings report date?
Kymera Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is in 62 days.
How were Kymera Therapeutics’s earnings last quarter?
Kymera Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.81 by -$0.14.
Is Kymera Therapeutics overvalued?
According to Wall Street analysts Kymera Therapeutics’s price is currently Undervalued.
Does Kymera Therapeutics pay dividends?
Kymera Therapeutics does not currently pay dividends.
What is Kymera Therapeutics’s EPS estimate?
Kymera Therapeutics’s EPS estimate is -0.74.
How many shares outstanding does Kymera Therapeutics have?
Kymera Therapeutics has 71,497,600 shares outstanding.
What happened to Kymera Therapeutics’s price movement after its last earnings report?
Kymera Therapeutics reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.81. Following the earnings report the stock price went down -7.238%.
Which hedge fund is a major shareholder of Kymera Therapeutics?
Currently, no hedge funds are holding shares in KYMR
Kymera Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.47 (45.46% Upside)
$61.47 (45.46% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 708.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $42.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.64%
12-Months-Change
Fundamentals
Return on Equity
-33.26%
Trailing 12-Months
Asset Growth
36.93%
Trailing 12-Months
Company Description
Kymera Therapeutics
Kymera Therapeutics (KYMR) is a biotechnology company focused on pioneering targeted protein degradation to develop novel therapeutics. Operating within the biopharmaceutical sector, Kymera aims to transform the treatment of diseases with high unmet medical needs, including cancer and immune-inflammatory diseases. The company's core products revolve around its proprietary drug discovery platform that leverages advanced protein degradation technology to selectively degrade disease-causing proteins.
KYMR Company Deck
KYMR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in Kymera's clinical programs and strategic collaborations, bolstering its financial position and setting the stage for future growth. Despite some uncertainties in dose selection and program transitions, the positive momentum and strong financial backing indicate a promising outlook.View all KYMR earnings summariesKYMR Stock 12 Month Forecast
Average Price Target
$61.47
▲(45.46% Upside)
Technical Analysis
BioCryst
―
Agios Pharma
―
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Ownership Overview
11.97% Insiders
29.59% Mutual Funds
0.72% Other Institutional Investors
45.16% Public Companies and
Individual Investors